AVBPClinical Trial Completion

ClinicalTrials.gov primary completion watch

ArriVent BioPharma | Furmonertinib | EGFR-mutant NSCLC

Catalyst details

Primary completion date tracked from linked public trial record.

Phase

Phase 3

Expected date

2026-12-15

Expected period

December 2026

Source type

clinicaltrials.gov

monthactive
Source URL

Notes

This record is structured for public-source tracking and manual analyst override. The database stores date confidence separately from exact dates so quarter, half-year, and estimated guidance can be handled without inventing precision.

Open company detail